- Home
- MEIP vs NMTC Comparison
MEIP vs NMTC Comparison
Compare MEIP & NMTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MEIP
- NMTC
- Stock Information
- Founded
- MEIP 2000
- NMTC 2009
- Country
- MEIP United States
- NMTC United States
- Employees
- MEIP N/A
- NMTC N/A
- Industry
- MEIP Biotechnology: Pharmaceutical Preparations
- NMTC Medical/Dental Instruments
- Sector
- MEIP Health Care
- NMTC Health Care
- Exchange
- MEIP Nasdaq
- NMTC Nasdaq
- Market Cap
- MEIP 17.1M
- NMTC 14.8M
- IPO Year
- MEIP 2003
- NMTC N/A
- Fundamental
- Price
- MEIP $1.98
- NMTC $0.59
- Analyst Decision
- MEIP Hold
- NMTC
- Analyst Count
- MEIP 1
- NMTC 0
- Target Price
- MEIP N/A
- NMTC N/A
- AVG Volume (30 Days)
- MEIP 11.6K
- NMTC 453.4K
- Earning Date
- MEIP 05-08-2025
- NMTC 05-13-2025
- Dividend Yield
- MEIP N/A
- NMTC N/A
- EPS Growth
- MEIP N/A
- NMTC N/A
- EPS
- MEIP N/A
- NMTC N/A
- Revenue
- MEIP N/A
- NMTC $5,749,521.00
- Revenue This Year
- MEIP N/A
- NMTC $292.88
- Revenue Next Year
- MEIP N/A
- NMTC N/A
- P/E Ratio
- MEIP N/A
- NMTC N/A
- Revenue Growth
- MEIP 33.76
- NMTC 104.21
- 52 Week Low
- MEIP $1.46
- NMTC $0.40
- 52 Week High
- MEIP $4.10
- NMTC $1.39
- Technical
- Relative Strength Index (RSI)
- MEIP 40.20
- NMTC 39.84
- Support Level
- MEIP $1.86
- NMTC $0.54
- Resistance Level
- MEIP $2.35
- NMTC $0.61
- Average True Range (ATR)
- MEIP 0.16
- NMTC 0.06
- MACD
- MEIP 0.02
- NMTC 0.01
- Stochastic Oscillator
- MEIP 68.42
- NMTC 37.82
About MEIP MEI Pharma Inc.
MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.
About NMTC NeuroOne Medical Technologies Corporation
NeuroOne Medical Technologies Corp operates as a medical technology company. It is focused on the development and commercialization of thin-film electrode technology for continuous electroencephalogram (cEEG) and stereoelectrocencephalography (sEEG) recording, brain stimulation, and ablation solutions for patients suffering from brain-related disorders. The company business is in one operating segment, which is the business of development and commercialization of products related to comprehensive neuromodulation cEEG and sEEG recording, monitoring, ablation, and brain stimulation solutions.